Biomarker research investigating genetic polymorphisms in drug-metabolizing enzymes (CYP2D6, CYP3A4) and neurotransmitter receptors could identify patients at highest risk for developing medication-induced bowel dysfunction, enabling personalized medicine approaches. Here, CYP3A4 is linked to bowel dysfunction.